|
|
Post by centralcoastinvestor on Sept 13, 2023 8:15:25 GMT -5
Mike also mentioned Pulmozyme and Roche at least a couple of times. That is a little exciting. I wonder if they are in talks at this point.
|
|
|
|
Post by letitride on Sept 13, 2023 8:33:07 GMT -5
I noticed Roche was looking for a partner for NTM as well wondering if they might step up and take a bite of us.
|
|
|
|
Post by Clement on Sept 13, 2023 9:10:04 GMT -5
Mike also mentioned Pulmozyme and Roche at least a couple of times. That is a little exciting. I wonder if they are in talks at this point. Pulmozyme - dornase alpha - cystic fibrosis Yeah, my ears went up when Mike started talking about this and I wondered about a possible partner. Didn't he de-emphasize dornase alpha about 6 months ago so that we could put resources into MNKD-101, -201, and -501? |
|
|
|
Post by tarheelblue004 on Sept 13, 2023 11:22:15 GMT -5
Great call! My key takeaways for new / potential investors:
1) Diversified company
2) Growing all revenue streams
3) Strong pipeline
4) Built foundation for long-term growth
5) Open to strategic partnerships
6) Large institutional ownership
7) No need for new capital
8) Management focus on market cap and SP
9) Starting to play in tech and AI
Low risk, high reward. Looking forward to the next class of investors starting to bite.
|
|
|
|
Post by uvula on Sept 13, 2023 11:35:20 GMT -5
I have a problem with saying no need for additional capital.
Mnkd would need additional capital to do the clinical trials necessary to get afrezza on the SOC for T1Ds and T2Ds.
The only reason they don't need more capital is because the first priority is to get to CFBE. MC keeps his job if the company keeps chugging along without any large expenses that would fuel future growth but would delay CFBE.
|
|
|
|
Post by Clement on Sept 13, 2023 11:49:17 GMT -5
Great conference call! I really think Mike was speaking the language of the larger institutional investors. Mike said that nearly 70% of the company stock is held by institutional investors. Now we are going after the bigger institutional investors. The Morgan Stanley conference is the right place to speak to the really large institutions. Way to go Mike! Mannkind website says 53%. Maybe the website needs updating? investors.mannkindcorp.com/stock-information/ownership-profile |
|
|
|
Post by sportsrancho on Sept 13, 2023 13:03:05 GMT -5
Goldman Sachs didn’t have any problem downgrading us to $1.00 when the stock was around $3, so they can sure as heck can upgrade us now even though we’re under $5
|
|
|
|
Post by peppy on Sept 13, 2023 13:50:36 GMT -5
I have a problem with saying no need for additional capital. Mnkd would need additional capital to do the clinical trials necessary to get afrezza on the SOC for T1Ds and T2Ds. The only reason they don't need more capital is because the first priority is to get to CFBE. MC keeps his job if the company keeps chugging along without any large expenses that would fuel future growth but would delay CFBE. From MnkdWASmyRtrmntPlan post. Mike, "We have lots of cash to continue to run our future and we feel that we don’t have any major needs for more capital to fund what we need to fund to grow our company." "Next year will have 2 readouts on Afrezza, and that will decide whether we can grow Afrezza faster than we have historically and are we willing to spend more capital to do that. We’ll make those calls once we see the data. The pipeline is in our funding forecast. We’re paying down our debt. We have done small deals on M&A and we will continue to look for things, but we have enough work to do on our hands, so we don’t need M&A to survive and it would be more of a distraction than a benefit. If we see something of interest, we’re not against it, but we feel very good about our future and capital allocation, which is to continue to invest in our growth brands, our pipelines and to pay down debt. "
mnkd.proboards.com/post/255961Steve Binder, our debt specialist? Oh and forget about T2's have you heard of OZEMPIC? T1's afrezza target. |
|
|
|
Post by uvula on Sept 13, 2023 14:34:46 GMT -5
Peppy, I think MC and I are saying the same thing. He had his usual positive spin and I had my usual realistic spin.
|
|
|
|
Post by prcgorman2 on Sept 13, 2023 17:46:57 GMT -5
Peppy, I think MC and I are saying the same thing. He had his usual positive spin and I had my usual realistic spin. I’ll agree you spun things (but that may not really be the case and instead just your POV [point of view]). I don’t think anybody at MNKD has said they need additional capital to do trials to change the Standard of Care. I think the focus has been on 2 existing trials and 1 new trial to influence prescribers especially. Those 3 trials are the Pediatric Trial, the Cipla regulatory approval trial, and the “pump switch” trial. The Cipla trial has been complete for some time but a readout has not yet been made available which might be normal or it might not. I don’t have any way to judge India regulatory approval trial timelines or information releases. The Pediatric trial got underway before COVID (and I assume was largely designed under the leadership of Dr. David Kendall). IIRC, that trial should wrap up next year with a readout next year or in 2025. I think the pump switch trial is in an early phase with a similar results/readout timeline as pediatric trial but I’ve not been following timelines closely so I welcome correction. Of those 3, the big hitter for T1s especially is the pediatric trial. There’s been speculation amongst those who post here that successful peds trial especially might be sufficient to change the SOC, but I don’t think I’ve heard MC or anyone at MNKD say that. I think they do expect positive results (duh) and that it should be influential. I like how MC couched it. I’ll summarize it as, we’ll see whether that “moves the needle” to decide what is appropriate investment in marketing Afrezza after those trials. I think he’s specifically zeroed in on peds and pump switch because those are here in the US and MNKD is paying for those. The Cipla trial was paid for by Cipla. |
|
|
|
Post by prcgorman2 on Sept 13, 2023 17:54:52 GMT -5
Definitely looking forward to the MS coverage and curious what the price target will be on the rec. GS coverage would be tasty icing on the cupcake. How do you know there will be Morgan Stanley coverage of MNKD? Is it really a slam-dunk? I continue to be skeptical but maybe you can persuade me. |
|
|
|
Post by mayday on Sept 13, 2023 17:59:32 GMT -5
That cretin is a half glass full kinda guy...
|
|
|
|
Post by sayhey24 on Sept 13, 2023 19:02:25 GMT -5
Didn't Aged say he was going to be in the audience today? From listening to the call I did not hear anything we have not heard before with the exception that Mike is now publicly talking about 10x-ing the company. That was great to hear.
|
|
|
|
Post by Thundersnow on Sept 13, 2023 20:19:41 GMT -5
Mike also mentioned Pulmozyme and Roche at least a couple of times. That is a little exciting. I wonder if they are in talks at this point. Pulmozyme - dornase alpha - cystic fibrosis Yeah, my ears went up when Mike started talking about this and I wondered about a possible partner. Didn't he de-emphasize dornase alpha about 6 months ago so that we could put resources into MNKD-101, -201, and -501? Yes he did but in this case he has to show all potential to Morgan Stanley. It's time for Mike to take the show on the road and PROMOTE MNKD. |
|
|
|
Post by Thundersnow on Sept 13, 2023 20:30:20 GMT -5
Definitely looking forward to the MS coverage and curious what the price target will be on the rec. GS coverage would be tasty icing on the cupcake. How do you know there will be Morgan Stanley coverage of MNKD? Is it really a slam-dunk? I continue to be skeptical but maybe you can persuade me. There's no guarantee that Morgan Stanley will initiate coverage but due to the fact that MNKD was INVITED to their conference and the stock price is BELOW $5.00 really sends a strong message that they are very interested in the company. Someone on Stocktwits made the observation that the MS Analyst was well versed on MNKD's history. That tells me they are very interested. |
|
